NDA 202155 · Bristol Myers Squibb
Eliquis
Apixaban · Oral · Factor Xa Inhibitor
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Jun 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Dec 28, 2012
Approved uses
5
Original approval plus efficacy supplements
Registered trials
283
83 Phase 3, 63 recruiting
FAERS reports
280,966
210,870 serious, 40,921 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS (B) SPINAL/EPIDURAL HEMATOMA (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see Dosage and Administration (2.4) , Warnings and Precautions (5.1) , and Clinical Studies (14.1) ] . (B) SPINAL/EPIDURAL HEMATOMA Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures....
What it is approved for
From the label in effect Sep 24, 2026.
ELIQUIS is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of DVT. 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of PE. 1.5 Reduction in the Risk of Recurrence of DVT and PE ELIQUIS is indicated to reduce the risk of recurrent DVT and PE following initial therapy.
Mechanism: Apixaban is a selective inhibitor of FXa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound FXa, and prothrombinase activity. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, apixaban decreases thrombin generation and thrombus development.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 17, 2025 Supplement 39 · Efficacy · priority review LetterLabel
- Apr 17, 2025 Supplement 40 · Efficacy · priority review OrphanLetterLabel
- Aug 21, 2014 Supplement 6 · Efficacy LetterLabel
- Mar 13, 2014 Supplement 3 · Efficacy LabelLetter
- Dec 28, 2012 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
3 products under this application
- ELIQUIS · APIXABAN 0.5MG · TABLET, FOR SUSPENSION, ORAL · Prescription
- ELIQUIS · APIXABAN 2.5MG · TABLET, ORAL · Prescription · TE AB
- ELIQUIS · APIXABAN 5MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Apixaban" as an intervention, any sponsor and status, largest first.
- Apixaban for the Prevention of Stroke in Subjects With Atrial FibrillationPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT00412984 · 20,976 participants · Start Dec 31, 2006 · Primary completion May 25, 2011
Drug: warfarin; apixaban · For: Atrial Fibrillation; Atrial Flutter
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 1,111 sites in all
- A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationPivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT05757869 · 20,284 participants · Start Apr 11, 2023 · Primary completion Dec 8, 2026
Drug: Milvexian; Apixaban and 2 more · For: Atrial Fibrillation
Sites: Alexander City, Alabama; Birmingham, Alabama; Dothan, Alabama · 1,052 sites in all
- Stroke and Systemic Embolism Prevention in Adult Participants With Atrial FibrillationPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07626411 · 15,364 participants (planned) · Start Aug 10, 2026 · Primary completion Sep 11, 2029
Drug: REGN7508; Apixaban and 1 more · For: Atrial Fibrillation (AF)
Sites: Alexander City, Alabama; Dothan, Alabama; Fairhope, Alabama · 84 sites in all
BayerBayer (BAYRY)
NCT05643573 · 14,830 participants · Start Dec 5, 2022 · Primary completion Jan 31, 2024
Drug: Asundexian (BAY2433334); Apixaban and 2 more · For: Prevention of Stroke or Systemic Embolism; Atrial Fibrillation
Sites: Dothan, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,069 sites in all
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial FibrillationPivotal-lookingActive, not recruiting
Herlev and Gentofte HospitalAcademic, hospital or other
NCT03129490 · 11,000 participants (planned) · Start Apr 1, 2023 · Primary completion Oct 30, 2027
Drug: Dabigatran Etexilate Oral Capsule; Rivaroxaban Oral Tablet and 2 more · For: Atrial Fibrillation; Atrial Flutter
Sites: Aalborg, Denmark; Aarhus, Denmark; Ballerup Municipality, Denmark · 38 sites in all
- Thromboprophylaxis in Lower Limb ImmobilisationPivotal-lookingRecruiting
Queen Mary University of LondonAcademic, hospital or other
NCT06370273 · 10,044 participants (planned) · Start Nov 12, 2024 · Primary completion Aug 31, 2028
Drug: Rivaroxaban; Apixaban and 4 more · For: Thrombosis; Injury Leg
Sites: Carshalton, United Kingdom; Hull, United Kingdom; London, United Kingdom · 5 sites in all
- Comparing the Safety and Efficacy of Apixaban and RivaroxabanPivotal-lookingRecruiting
VA Office of Research and DevelopmentFederal agency
NCT06953726 · 10,000 participants (planned) · Start Jun 1, 2026 · Primary completion Oct 4, 2032
Drug: Apixaban; Rivaroxaban · For: Atrial Fibrillation
Sites: West Los Angeles, California; Miami, Florida; Boston, Massachusetts · 9 sites in all
- Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular EventsPivotal-lookingStatus unknown
Xijing HospitalAcademic, hospital or other
NCT01924325 · 10,000 participants (planned) · Start Jan 2014 · Primary completion Dec 2015
Drug: Apixaban; Clopidogrel and 2 more · For: Ischemic Stroke; TIA
Sites: Xi'an, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death25,095
- dyspnoea13,002
- fatigue12,518
- off label use12,368
- atrial fibrillation10,940
- diarrhoea10,264
- fall9,795
- cerebrovascular accident9,076
- dizziness9,007
- nausea8,776
- headache7,976
- thrombosis7,555
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2007 | 2 |
| 2008 | 7 |
| 2009 | 20 |
| 2010 | 36 |
| 2011 | 117 |
| 2012 | 26 |
| 2013 | 1,174 |
| 2014 | 3,800 |
| 2015 | 7,567 |
| 2016 | 12,344 |
| 2017 | 17,213 |
| 2018 | 21,671 |
| 2019 | 27,146 |
| 2020 | 30,826 |
| 2021 | 34,744 |
| 2022 | 29,838 |
| 2023 | 26,565 |
| 2024 | 26,750 |
| 2025 | 23,878 |
| 2026 | 17,241 |
Recalls
1 FDA enforcement reports for this application.
Jun 5, 2017 · Class I · Terminated
Labeling: Label Mix-up: One bottle of Eliquis 5 mg tablet was found to contain lower-strength Eliquis 2.5 mg tablets only instead of the labeled 5 mg tablets.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Eliquis (Apixaban)
2024 spending
$20.8B
Beneficiaries
4,424,796
24,061,332 claims
Per beneficiary
$4,695
$9.64 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $9,936,069,814 |
| 2021 | $12,575,145,852 |
| 2022 | $15,219,812,294 |
| 2023 | $18,273,451,967 |
| 2024 | $20,774,929,225 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism.
Castellucci LA, Chen VM, Kovacs MJ, et al. · N Engl J Med 2026 · Clinical Trial, Phase IV, Comparative Study
- Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism.
Mahé I, Carrier M, Mayeur D, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Equivalence Trial
- Apixaban for Extended Treatment of Provoked Venous Thromboembolism.
Piazza G, Bikdeli B, Pandey AK, et al. · N Engl J Med 2025 · Clinical Trial, Phase IV, Randomized Controlled Trial
- Apixaban versus warfarin in patients with atrial fibrillation.
Granger CB, Alexander JH, McMurray JJ, et al. · N Engl J Med 2011 · Comparative Study, Multicenter Study
- Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA.
Lopes RD, Granger CB, Wojdyla DM, et al. · J Am Coll Cardiol 2024 · Randomized Controlled Trial, Comparative Study
- Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation.
Healey JS, Lopes RD, Granger CB, et al. · N Engl J Med 2024 · Comparative Study, Randomized Controlled Trial
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.